Analyst lifts Eli Lilly price target to $1,400, citing continued momentum in its GLP-1 lineup

Eli Lilly (LLY) climbed in Tuesday’s trading after JPMorgan analyst Chris Schott raised his price target for the pharmaceutical company to $1,400 from $1,300, reiterating an Overweight rating, according to market coverage.

The analyst’s note, as summarized by Yahoo Finance, was cited as the key driver behind the stock’s afternoon jump of roughly 2.8%. Schott’s new target implies continued upside versus where the market was setting consensus expectations, with the target described as sitting above an estimated Street average of about $1,243 in the coverage.

In laying out the rationale, the same report emphasized Lilly’s GLP-1 franchise, arguing that the category still has room to expand. The note credited international expansion of Mounjaro, Eli Lilly’s GLP-1 based diabetes and obesity-linked therapy, alongside what the report characterized as durable domestic demand for Zepbound, Lilly’s branded weight-loss option in the U.S.

The coverage also highlighted Lilly’s broader pipeline beyond its current injection-based treatments. It pointed to the company’s oral program orforglipron, marketed as Foundayo in the report, and to retatrutide, described as a triple-agonist candidate, as examples of the kinds of next-generation incretin products that could extend the franchise over time.

Beyond drug development, the market narrative in the report tied the near-term outlook to access and coverage developments. It referenced Medicare’s GLP-1 Bridge program starting July 1, 2026, which the coverage described as providing access to Zepbound and Foundayo with a $50 monthly copay for eligible participants.

The report also connected momentum in Lilly’s oncology work to recent regulatory progress, mentioning that the European Medicines Agency committee for human medicines had backed Lilly’s cancer drug Jaypirca. The summary described the positive opinion as for chronic lymphocytic leukemia and said it was a step toward final approval across the European Union, which the report expected within roughly two months.

While none of these points were presented as company-specific new disclosures on Tuesday, they reflect how analysts were framing the company’s growth profile: a mix of commercial execution in obesity and diabetes and a pipeline designed to preserve share as new therapies reach patients.

As with many single-day moves, traders may watch whether the stock’s reaction holds as investors parse whether the Street’s assumptions are shifting or whether the catalyst is mainly a sentiment boost from JPMorgan’s adjustment.